Q2 revenue grew 11% year-over-year to $201.7 million, driven by 14% clinical revenue growth and 26% NGS growth. Gross margin expanded 260 basis points, and adjusted EBITDA rose 36%. Full-year 2026 guidance was raised for both revenue and EBITDA, reflecting strong clinical momentum and margin improvements.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.